Pfizer Inc. (NYSE:PFE) Shares Sold by Associated Banc Corp

Associated Banc Corp cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 11.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 223,962 shares of the biopharmaceutical company’s stock after selling 27,951 shares during the quarter. Associated Banc Corp’s holdings in Pfizer were worth $5,942,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Swedbank AB boosted its position in Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after acquiring an additional 37,636 shares during the last quarter. United Bank raised its stake in Pfizer by 3.7% during the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after purchasing an additional 1,277 shares during the period. GSA Capital Partners LLP raised its stake in Pfizer by 87.6% during the third quarter. GSA Capital Partners LLP now owns 32,786 shares of the biopharmaceutical company’s stock worth $949,000 after purchasing an additional 15,310 shares during the period. Curi RMB Capital LLC raised its stake in Pfizer by 4.7% during the third quarter. Curi RMB Capital LLC now owns 55,770 shares of the biopharmaceutical company’s stock worth $1,614,000 after purchasing an additional 2,487 shares during the period. Finally, Oak Harbor Wealth Partners LLC raised its stake in Pfizer by 3.3% during the third quarter. Oak Harbor Wealth Partners LLC now owns 73,828 shares of the biopharmaceutical company’s stock worth $2,137,000 after purchasing an additional 2,375 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 0.5 %

Shares of NYSE:PFE opened at $25.74 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market capitalization of $145.85 billion, a PE ratio of 18.25, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The firm’s 50-day moving average is $26.24 and its two-hundred day moving average is $27.15. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the firm earned $0.10 earnings per share. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on PFE. UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Finally, Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.